270 related articles for article (PubMed ID: 15927285)
1. Early abciximab administration in acute myocardial infarction treated with primary coronary intervention.
Bellandi F; Maioli M; Leoncini M; Toso A; Dabizzi RP
Int J Cardiol; 2006 Mar; 108(1):36-42. PubMed ID: 15927285
[TBL] [Abstract][Full Text] [Related]
2. Increase of myocardial salvage and left ventricular function recovery with intracoronary abciximab downstream of the coronary occlusion in patients with acute myocardial infarction treated with primary coronary intervention.
Bellandi F; Maioli M; Gallopin M; Toso A; Dabizzi RP
Catheter Cardiovasc Interv; 2004 Jun; 62(2):186-92. PubMed ID: 15170708
[TBL] [Abstract][Full Text] [Related]
3. Randomized early versus late abciximab in acute myocardial infarction treated with primary coronary intervention (RELAx-AMI Trial).
Maioli M; Bellandi F; Leoncini M; Toso A; Dabizzi RP
J Am Coll Cardiol; 2007 Apr; 49(14):1517-24. PubMed ID: 17418289
[TBL] [Abstract][Full Text] [Related]
4. Early administration of abciximab bolus in the emergency department improves angiographic outcome after primary PCI as assessed by TIMI frame count: results of the early ReoPro administration in myocardial infarction (ERAMI) trial.
Gabriel HM; Oliveira JA; da Silva PC; da Costa JM; da Cunha JA
Catheter Cardiovasc Interv; 2006 Aug; 68(2):218-24. PubMed ID: 16817177
[TBL] [Abstract][Full Text] [Related]
5. Comparison of abciximab and eptifibatide on angiographic and clinical outcomes in rescue percutaneous coronary intervention for failed fibrinolytic therapy.
Bajaj RR; Mohammad A; Hong T; Irfan A; Sharieff W; Bagnall A; Christie JA; Kutryk MJ; Chisholm RJ; Cheema AN
J Invasive Cardiol; 2010 Aug; 22(8):347-52. PubMed ID: 20679668
[TBL] [Abstract][Full Text] [Related]
6. Facilitated primary coronary intervention with abciximab and very low dose of alteplase during off-hours compared with direct primary intervention during regular hours.
Maioli M; Gallopin M; Leoncini M; Bellandi F; Toso A; Dabizzi RP
Catheter Cardiovasc Interv; 2005 Aug; 65(4):484-91. PubMed ID: 15973688
[TBL] [Abstract][Full Text] [Related]
7. Early administration of abciximab in patients with acute myocardial infarction improves angiographic and clinical outcome after primary angioplasty.
Beeres SL; Oemrawsingh PV; Warda HM; Bechan R; Atsma DE; Jukema JW; van der Wall EE; Schalij MJ
Catheter Cardiovasc Interv; 2005 Aug; 65(4):478-83. PubMed ID: 15973655
[TBL] [Abstract][Full Text] [Related]
8. Early abciximab administration before primary percutaneous coronary intervention improves infarct-related artery patency and left ventricular function in high-risk patients with anterior wall myocardial infarction: a randomized study.
Rakowski T; Zalewski J; Legutko J; Bartus S; Rzeszutko L; Dziewierz A; Sorysz D; Bryniarski L; Zmudka K; Kaluza GL; Dubiel JS; Dudek D
Am Heart J; 2007 Mar; 153(3):360-5. PubMed ID: 17307412
[TBL] [Abstract][Full Text] [Related]
9. Comparison in patients having primary coronary angioplasty of abciximab versus tirofiban on recovery of left ventricular function.
Danzi GB; Sesana M; Capuano C; Mauri L; Berra Centurini P; Baglini R
Am J Cardiol; 2004 Jul; 94(1):35-9. PubMed ID: 15219505
[TBL] [Abstract][Full Text] [Related]
10. In-ambulance abciximab administration in STEMI patients prior to primary PCI is associated with smaller infarct size, improved LV function and lower incidence of heart failure: results from the Leiden MISSION! acute myocardial infarction treatment optimization program.
Hassan AK; Liem SS; van der Kley F; Bergheanu SC; Wolterbeek R; Bosch J; Bootsma M; Zeppenfeld K; van der Laarse A; Atsma DE; Jukema JW; Schalij MJ
Catheter Cardiovasc Interv; 2009 Aug; 74(2):335-43. PubMed ID: 19642182
[TBL] [Abstract][Full Text] [Related]
11. Evaluation of infarct-related coronary artery patency and microcirculatory function after facilitated percutaneous primary coronary angioplasty: the FINESSE-ANGIO (Facilitated Intervention With Enhanced Reperfusion Speed to Stop Events-Angiographic) study.
Prati F; Petronio S; Van Boven AJ; Tendera M; De Luca L; de Belder MA; Galassi AR; Imola F; Montalescot G; Peruga JZ; Barnathan ES; Ellis S; Savonitto S;
JACC Cardiovasc Interv; 2010 Dec; 3(12):1284-91. PubMed ID: 21232723
[TBL] [Abstract][Full Text] [Related]
12. Left ventricular function after ST-elevation myocardial infarction in patients treated with primary percutaneous coronary intervention and abciximab or tirofiban (from the Facilitated Angioplasty with Tirofiban or Abciximab [FATA] Trial).
Taglieri N; Saia F; Guiducci V; Tondi S; Conrotto F; Marrozzini C; Rocchi G; Biagini E; Reggiani ML; Giacometti P; Piovaccari G; Manari A; Marzocchi A;
Am J Cardiol; 2009 Mar; 103(6):785-90. PubMed ID: 19268732
[TBL] [Abstract][Full Text] [Related]
13. Abciximab in patients with acute ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention after clopidogrel loading: a randomized double-blind trial.
Mehilli J; Kastrati A; Schulz S; Früngel S; Nekolla SG; Moshage W; Dotzer F; Huber K; Pache J; Dirschinger J; Seyfarth M; Martinoff S; Schwaiger M; Schömig A;
Circulation; 2009 Apr; 119(14):1933-40. PubMed ID: 19332467
[TBL] [Abstract][Full Text] [Related]
14. Prospective randomised study to evaluate effectiveness of distal embolic protection compared to abciximab administration in reduction of microembolic complications of primary coronary angioplasty.
Ochała A; Smolka G; Wojakowski W; Gabrylewicz B; Garbocz P; Tendera M
Kardiol Pol; 2007 Jun; 65(6):672-80; discussion 681-3. PubMed ID: 17629829
[TBL] [Abstract][Full Text] [Related]
15. Frequency, correlates, and clinical implications of myocardial perfusion after primary angioplasty and stenting, with and without glycoprotein IIb/IIIa inhibition, in acute myocardial infarction.
Costantini CO; Stone GW; Mehran R; Aymong E; Grines CL; Cox DA; Stuckey T; Turco M; Gersh BJ; Tcheng JE; Garcia E; Griffin JJ; Guagliumi G; Leon MB; Lansky AJ
J Am Coll Cardiol; 2004 Jul; 44(2):305-12. PubMed ID: 15261923
[TBL] [Abstract][Full Text] [Related]
16. Intracoronary versus intravenous administration of abciximab in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention with thrombus aspiration: the comparison of intracoronary versus intravenous abciximab administration during emergency reperfusion of ST-segment elevation myocardial infarction (CICERO) trial.
Gu YL; Kampinga MA; Wieringa WG; Fokkema ML; Nijsten MW; Hillege HL; van den Heuvel AF; Tan ES; Pundziute G; van der Werf R; Hoseyni Guyomi S; van der Horst IC; Zijlstra F; de Smet BJ
Circulation; 2010 Dec; 122(25):2709-17. PubMed ID: 21098442
[TBL] [Abstract][Full Text] [Related]
17. Intracoronary versus intravenous bolus abciximab application in patients with ST-elevation myocardial infarction undergoing primary percutaneous coronary intervention: 6-month effects on infarct size and left ventricular function. The randomised Leipzig Immediate PercutaneouS Coronary Intervention Abciximab i.v. versus i.c. in ST-Elevation Myocardial Infarction Trial (LIPSIAbciximab-STEMI).
Eitel I; Friedenberger J; Fuernau G; Dumjahn A; Desch S; Schuler G; Thiele H
Clin Res Cardiol; 2011 May; 100(5):425-32. PubMed ID: 21125288
[TBL] [Abstract][Full Text] [Related]
18. Abciximab in the treatment of acute myocardial infarction eligible for primary percutaneous transluminal coronary angioplasty. Results of the Glycoprotein Receptor Antagonist Patency Evaluation (GRAPE) pilot study.
van den Merkhof LF; Zijlstra F; Olsson H; Grip L; Veen G; Bär FW; van den Brand MJ; Simoons ML; Verheugt FW
J Am Coll Cardiol; 1999 May; 33(6):1528-32. PubMed ID: 10334418
[TBL] [Abstract][Full Text] [Related]
19. Early vs late administration of glycoprotein IIb/IIIa inhibitors in primary percutaneous coronary intervention of acute ST-segment elevation myocardial infarction: a meta-analysis.
Montalescot G; Borentain M; Payot L; Collet JP; Thomas D
JAMA; 2004 Jul; 292(3):362-6. PubMed ID: 15265852
[TBL] [Abstract][Full Text] [Related]
20. Platelet glycoprotein IIb/IIIa inhibition with coronary stenting for acute myocardial infarction.
Montalescot G; Barragan P; Wittenberg O; Ecollan P; Elhadad S; Villain P; Boulenc JM; Morice MC; Maillard L; Pansiéri M; Choussat R; Pinton P;
N Engl J Med; 2001 Jun; 344(25):1895-903. PubMed ID: 11419426
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
